No Data
No Data
Express News | Annexon to Present Significant Phase 3 Results of ANX005 in Guillain-Barré Syndrome at PNS Annual Meeting; Potential to Be First Targeted Therapy for GBS
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating
Wells Fargo analyst Derek Archila maintains $Annexon(ANNX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.2% and a total average return of 5.6% over the past ye
BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $12
BofA Securities analyst Tazeen Ahmad maintains $Annexon(ANNX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 48.3% and a tot
Express News | Annexon Shares Are Trading Lower After the Company Announced the Pricing of a $125 Milion Underwritten Public Offering of 13,001,120 Shares at $6.25 per Share
No Data